Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.
Changes to biologics manufacturing will have to go beyond swapping steel vats for single-use to adapt to future industry needs, says Amgen’s drug development expert.
West Pharmaceutical Services is sticking with plans to lessen CMO (contract manufacturing organisation) activities and boost proprietary products despite a hefty uptick in contract production in Q2.
Oxford Biomedica has bought RecipharmCobra Biologics’ manufacturing facility in Oxford, UK, to reduce its reliance on third-party production of its gene delivery technology.
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.